Form 10-K for the Fiscal Year Ended December 31, 2023
We note your measure of Covenant Adjusted EBITDA includes adjustments for the change in deferred revenue and change in deferred costs of revenue. You disclose that this measure is used in certain covenant calculations specified in the indenture governing your senior notes due 2030.Rest of the question
As indicated in our comment letter dated April 21, 2023, to the extent you believe this measure is material to an investor’s understanding of your financial condition and/or liquidity, you should limit any discussion of such measure to the liquidity section in your filed documents (i.e. Forms 10-K and 10-Q). As such, please remove any reference to Covenant Adjusted EBITDA from your earnings releases and shareholder letters included in your Forms 8-K, as well as discussions elsewhere such as in earnings calls and other supplemental information. Refer to Question 102.09 of the Non-GAAP C&DIs. Alternatively, revise the measure used outside of the liquidity discussion in your filed documents and remove the adjustments for change in deferred revenue and change in deferred cost of revenue as these adjustments result in a measure that reflects individually tailored recognition methods. Refer to Rule 100(b) of Regulation G and Question 100.04 of the Non-GAAP CD&Is.
No reply letter found.
First report after the SEC's letter of Apr 12, 2024: 10-Q filed May 9, 2024 ↗, against the 10-Q filed Nov 8, 2023 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
We note your response to prior comment 1. We continue to believe you should limit any discussion of Covenant Adjusted EBITDA to the liquidity section in your filed documents (i.e. Forms 10-K and 10-Q). Please remove any reference to Covenant Adjusted EBITDA from your earnings releases and shareholder letters included in your Forms 8-K, as well as elsewhere such as in earnings calls and other supplementalRest of the question
information. Refer to Question 102.09 of the Non-GAAP C&DIs. Alternatively, revise the measure used outside of the liquidity discussion in your filed documents to remove the adjustments for change in deferred revenue and change in deferred cost of revenue as these adjustments result in a measure that reflects individually tailored recognition methods. Refer to Rule 100(b) of Regulation G and Question 100.04 of the Non-GAAP CD&Is.
We continue to believe that Covenant Adjusted EBITDA is an important calculation for our debtholders, investors, and management team in understanding and evaluating our financial condition and liquidity and therefore should be included in separately captioned liquidity sections across our quarterly earnings releases, shareholder letters and supplemental materials in the interest of full and fair disclosure.Read in the reply
However, acknowledging the Staff’s comment, we respectfully advise the Staff that we will remove references to Covenant Adjusted EBITDA from our earnings releases and shareholder lettersRest of the answer
included with our Form 8-K, as well as elsewhere such as in our prepared remarks on our earnings calls and other supplemental information, beginning with the quarterly period ended March 31, 2024.
* * * *
If you require any additional information on the matters contained in this letter, or if we can provide you with any other information that will facilitate your review, please advise us at your earliest convenience. You may reach me at [email protected].
First report after the company's reply of May 1, 2024: 10-Q filed May 9, 2024 ↗, against the 10-Q filed Nov 8, 2023 ↗.
Tickdelta does not hold the text of both reports, so they are not compared here.
Also in this review: closing letter, 2024-05-09